Compare BridgeBio Pharma Inc (BBIO) vs Fox Corp Class A (FOXA) Price & Performance

BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.

Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.

FOXA trades at $55.9, up 3.29% today, with a bearish technical signal but strong fundamental performance including three consecutive quarterly earnings beats. Revenue grew to $16.3B in 2025, with net income margin expanding to 13.88%. The company's acquisition of Roku for $22 billion marks a strategic pivot into streaming distribution, though it introduces leverage risk.

The outlook is mixed: analyst consensus targets $67.80 (21% upside) with a 50/50 buy/hold split, but 2026 forecasts show declining cash flow and earnings. Key risks include integration challenges from the Roku deal and streaming competition. Upside hinges on successful execution of the new strategy and advertising momentum.